SynAct Pharma AB

Redeye: SynAct Pharma - Adding an indication

Mon, Oct 28, 2019 07:52 CET

We had the opportunity to dig deeper in to the commercial potential for AP1189 in nephrotic syndrome. As a result, we raise our base case valuation to SEK 17 per share. Read more and download the research update: http://bit.ly/2WilqLy Start following companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Redeye initiates coverage of SynAct Pharma

Tue, Oct 01, 2019 08:03 CET

We initiate coverage of SynAct Pharma, a phase II biotech targeting the USD 20 billion+ rheumatoid arthritis market with its lead candidate AP1189. The SynAct team have successfully taken compounds through Phase I and II together before and has skin in the game, sitting on more than 30% of the shares. While nearer-term upside is limited by the company’s need for new capital this year, our risk-adjusted DCF model suggests a base valuation of SEK 13 per share, which comparison with peers supports as SynAct trades at a discount to other Swedish Phase II biotechs. Read more and download the

Share

Redeye: SynAct Pharma - Adding an indication

Redeye initiates coverage of SynAct Pharma